Loading...
Please wait, while we are loading the content...
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
| Content Provider | Europe PMC |
|---|---|
| Author | Paz-Ares, L. Barlesi, F. Siena, S. Ahn, M.-J. Drilon, A. Conley, A. Rolfo, C. Wolf, J. Seto, T. Doebele, R. Kapre, A. Chen, D. McCallum, S. Osborne, S. Demetri, G. |
| Copyright Year | 2021 |
| Journal | ESMO Open |
| Volume Number | 6 |
| PubMed Central reference number | PMC8100628 |
| Issue Number | 3 |
| PubMed reference number | 33930659 |
| e-ISSN | 20597029 |
| DOI | 10.1016/j.esmoop.2021.100113 |
| Language | English |
| Publisher | BMJ |
| Publisher Date | 2021-04-27 |
| Access Restriction | Open |
| Rights License | This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). © 2021 The Authors |
| Subject Keyword | entrectinib NTRK patient-reported outcomes ROS1 tyrosine kinase inhibitor |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Cancer Research |